Lilly Prepares Amylin-Based Obesity Drug Eloralintide for Phase III After Strong Weight Loss Results

Eli Lilly is preparing to launch Phase III clinical trials of its amylin-based obesity drug candidate eloralintide next month, following strong efficacy in Phase II trials63.

In the Phase II trial, eloralintide at the highest tested dose (9 mg) resulted in a mean weight loss of 20.1% after 48 weeks, significantly outperforming placebo and exceeding analyst expectations53.

Placebo-adjusted weight loss reported in the study ranged from 16% to 20% at 48 weeks, which is considered better than anticipated compared to existing GLP-1 therapies1.

Lower doses in the same trial resulted in a mean weight loss from 9% to 20%, while the placebo group only saw a 0.4% reduction in body weight5.

The move to Phase III will be based on these results, with Lilly expected to begin enrolling patients in the new studies imminently6.

Sources:

1. https://www.bioworld.com/articles/725875-lillys-amylin-drug-heads-to-phase-iii-on-strong-weight-loss-data

3. https://www.biospace.com/drug-development/lillys-amylin-agonist-headed-to-phase-iii-after-eliciting-up-to-20-weight-loss

5. https://www.appliedclinicaltrialsonline.com/view/eli-lilly-trial-eloralintide-weight-reduction-adults-obesity

6. https://insights.citeline.com/scrip/r-and-d/clinical-trials/lilly-plans-phase-iii-trials-after-positive-results-from-amylin-drug-eloralintide-7UEKW77OGNHMZPIQHE5SZ5LQHY/